Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis

Peritoneal Dialysis International

Volumn 33, Issue 3, 2013, Pages 242-251

  Kawanishi, Kunio ^a   Honda, Kazuho ^a   Tsukada, Misao ^a   Oda, Hideaki ^a   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

AGEs; Angiogenesis; Biocompatible solution; GDPs; Peritoneal fibrosis; Vascular sclerosis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CD31 ANTIGEN; DIANEAL; DIANEAL N; PERISATE; PERITONEAL DIALYSIS FLUID; PODOPLANIN; UNCLASSIFIED DRUG;

ADULT; ARTERIOSCLEROSIS; ARTICLE; BIOACCUMULATION; BIOCOMPATIBILITY; CAPILLARY DENSITY; CATHETERIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PERITONEAL DIALYSIS; PERITONEAL DIALYSIS CATHETER; PERITONEAL FIBROSIS; PERITONEUM; PRIORITY JOURNAL; QUANTITATIVE STUDY; TISSUE DISTRIBUTION; ULTRAFILTRATION;

AGES; ANGIOGENESIS; BIOCOMPATIBLE SOLUTION; GDPS; PERITONEAL FIBROSIS; VASCULAR SCLEROSIS;

ADULT; BICARBONATES; BIOCOMPATIBLE MATERIALS; BLOOD VESSELS; CAPILLARIES; DIALYSIS SOLUTIONS; FEMALE; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEUM; SCLEROSIS; ULTRAFILTRATION;

EID: 84878993223     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2011.00270     Document Type: Article

References (29)

1. Jörres A, Bender TO, Finn A, Witowski J, Fröhlich S, Gahl GM, et al. Biocompatibility and buffers: effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function. Kidney Int 1998; 54:2184-93.
2. Jörres A, Witowski J. Lessons from basic research for PD treatment. Perit Dial Int 2005; 25(Suppl 3):S35-8.
3. Topley N, Kaur D, Petersen MM, Jörres A, Williams JD, Faict D, et al. In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial and neutrophil function. J Am Soc Nephrol 1996; 7:218-24.
4. Combet S, Miyata T, Moulin P, Pouthier D, Goffin E, Devuyst O. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. J Am Soc Nephrol 2000; 11:717-28.
5. Pecoits-Filho R, Araújo MR, Lindholm B, Stenvinkel P, Abensur H, Romão JE Jr, et al. Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant 2002; 17:1480-6.
6. Rougier JP, Guia S, Hagège J, Nguyen G, Ronco PM. PAI-1 secretion and matrix deposition in human peritoneal mesothelial cell cultures: transcriptional regulation by TGF-β1. Kidney Int 1998; 54:87-98.
7. Aroeira LS, Aguilera A, Selgas R, Ramírez-Huesca M, Pérez-Lozano ML, Cirugeda A, et al. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. Am J Kidney Dis 2005; 46:938-48.
8. Devuyst O, Combet S, Cnops Y, Stoenoiu MS. Regulation of NO synthase isoforms in the peritoneum: implications for ultrafiltration failure in peritoneal dialysis. Nephrol Dial Transplant 2001; 16:675-8.
9. Garcia-Lopez E, Lindholm B, Tranæus A. Biocompatibility of new peritoneal dialysis solutions: clinical experience. Perit Dial Int 2000; 20(Suppl 5):S48-56.
10. Nakamoto H, Imai H, Ishida Y, Yamanouchi Y, Inoue T, Okada H, et al. New animal models for encapsulating peritoneal sclerosis-role of acidic solution. Perit Dial Int 2001; 21(Suppl 3):349-53.
11. López-Novoa JM, Bernabeu C. The physiological role of endoglin in the cardiovascular system. Am J Physiol Heart Circ Physiol 2010; 299:H959-74.
12. Mortier S, Faict D, Schalkwijk CG, Lameire NH, De Vriese AS. Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 2004; 66:1257-65.
13. Krediet RT, Zweers MM, van Westrhenen R, Zegwaard A, Struijk DG. Effects of reducing the lactate and glucose content of PD solutions on the peritoneum. Is the future GLAD? NDT Plus 2008; 1(Suppl 4): iv 56-62.
14. Rippe B, Simonsen O, Heimbürger O, Christensson A, Haraldsson B, Stelin G, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59:348-57.
15. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane. Kidney Int 2004; 66:408-18.
16. Honda K, Hamada C, Nakayama M, Miyazaki M, Sherif AM, Harada T, et al. Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology. Clin J Am Soc Nephrol 2008; 3:720-8.
17. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14:1541-9.
18. Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001; 12:1046-51.
19. van Westrhenen R, Zweers MM, Kunne C, de Waart DR, van der Wal AC, Krediet RT. A pyruvate-buffered dialysis fluid induces less peritoneal angiogenesis and fibrosis than a conventional solution. Perit Dial Int 2008; 28:487-96.
20. van Westrhenen R, Vlijm A, Hiralall JK, Krediet RT. Experimental study on long-term exposure to a biocompatible, hypertonic, pyruvate-buffered dialysis solution. Perit Dial Int 2008; 28(Suppl 5):S43-7.
21. Rippe B. Peritoneal angiogenesis in response to dialysis fluid. Contrib Nephrol 2009; 163:60-6.
22. Mateijsen MA, van der Wal AC, Hendriks PM, Zweers MM, Mulder J, Struijk DG, et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999; 19:517-25.
23. Simonsen O, Sterner G, Carlsson O, Wieslander A, Rippe B. Improvement of peritoneal ultrafiltration with peritoneal dialysis solution buffered with bicarbonate/lactate mixture. Perit Dial Int 2006; 26:353-9.
24. Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranæus A, et al. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59:1529-38.
25. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
26. Sherif AM, Nakayama M, Maruyama Y, Yoshida H, Yamamoto H, Yokoyama K, et al. Quantitative assessment of the peritoneal vessel density and vasculopathy in CAPD patients. Nephrol Dial Transplant 2006; 21:1675-81.
27. Numata M, Nakayama M, Nimura S, Kawakami M, Lindholm B, Kawaguchi Y, et al. Association between an increased surface area of peritoneal microvessels and a high peritoneal solute transport rate. Perit Dial Int 2003; 23:116-22.
28. Sakamoto I, Ito Y, Mizuno M, Suzuki Y, Sawai A, Tanaka A, et al. Lymphatic vessels develop during tubulointerstitial fibrosis. Kidney Int 2009; 75:828-38.
29. Fabbrini P, Schilte MN, Zareie M, ter Wee PM, Keuning ED, Beelen RH, et al. Celecoxib treatment reduces peritoneal fibrosis and angiogenesis and prevents ultrafiltration failure in experimental peritoneal dialysis. Nephrol Dial Transplant 2009; 24:3669-76.